Boston Scientific Corp. - BSX STOCK NEWS

Boston Scientific recently highlighted the importance of equity and inclusion in the workplace in celebration of International Women's Day.

The company shared three significant moments that illustrate how leaders can foster an inclusive culture. Key learnings include the value of vulnerability to build trust, the necessity of including diverse voices in discussions about diversity, equity, and inclusion (DEI), and the power of small acts in creating an inclusive environment.

These insights aim to inspire other organizations to embrace equity actively and empower all employees to be their authentic selves.

Boston Scientific emphasizes the importance of diversity in clinical trials to enhance patient outcomes. In a joint effort with Medtronic, the companies aim to increase representation among trial participants to reflect the diverse populations they serve. Laura Mauri, MD, from Medtronic, highlighted that inclusive representation is essential not only for addressing health inequities but also for understanding product efficacy across varied demographics. This strategic focus on diverse clinical trials aims to improve treatment effectiveness and outcomes for a broader patient base.

Boston Scientific highlights challenges faced by transgender employees in the workplace, as illustrated by the experiences of Trevor Boylston, who transitioned a decade before joining the company. After encountering negative comments about his gender identity, Boylston advocated for inclusivity and understanding among coworkers. The press release features an event focused on the transgender community, aimed at fostering positive employment experiences and addressing workplace discrimination. It underscores the importance of supporting diverse identities in professional settings, particularly in light of ongoing societal changes.

Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on March 1, 2023. The event will feature a 40-minute question-and-answer session with key executives, Dan Brennan, Chief Financial Officer, and Lauren Tengler, Vice President of Investor Relations, at 8:00 a.m. EST. Interested parties can access a live webcast of the session through the Boston Scientific Investor Relations website, with a replay available one hour post-event. Boston Scientific is dedicated to transforming lives with innovative medical solutions and has been a leader in medical technology for over 40 years.

Boston Scientific emphasizes the importance of career strategies amidst the growing trend of work-life integration. As caregiving responsibilities, particularly among women, have come to the forefront during recent years, the company highlights the need for discussions surrounding career management. According to the CDC, two out of every three caregivers in the U.S. are women, who provide significant support for children and adults with various needs. The press release calls for a renewed focus on how individuals can take charge of their career paths in this evolving landscape.

Boston Scientific Corporation (NYSE: BSX) announced FDA 510(k) clearance for the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first system to monitor intrarenal pressure in real-time during ureteroscopy. Ureteroscopy is vital for treating kidney stones, affecting about 10% of people. The new system aims to reduce complications from elevated intrarenal pressure, which can lead to severe post-operative issues. Enhancements include improved image quality, updated control features, and streamlined integration with existing operating room systems. Limited market release in the U.S. will begin soon.

Boston Scientific generated net sales of $3.242 billion in Q4 2022, increasing by 3.7% year-over-year. The results reflect an 8.7% operational and 7.1% organic growth, despite a 200 basis point impact from Italian payback provisions. GAAP net income was $126 million or $0.09 EPS, lower than expected guidance. For 2022, total net sales reached $12.682 billion, a 6.7% growth, but GAAP net income fell to $642 million or $0.45 EPS. The company anticipates 5% to 7% net sales growth in 2023 and has announced acquisitions to expand its portfolio.

Boston Scientific Corporation (NYSE: BSX) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST in San Francisco, California. CEO Mike Mahoney will present alongside other key executives. Additionally, the company will host a conference call on February 1, 2023, at 8:00 a.m. EST, to discuss its fourth-quarter financial results for the period ending December 31, 2022. A news release will precede this call, providing financial highlights.